EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Early Effects of Scaling Up Dolutegravir-Based ARV Regimens Among Children Living with HIV in Malawi

Lucky Makonokaya, Alice Maida, Louiser Upile Kalitera, Alice Wang, Lester Kapanda, Dumbani Kayira, Madalitso Bottoman, Harrid Nkhoma, Shalom Dunga, Zuze Joaki, Rachel Chamanga, Kondwani Nkanaunena und 7 weitere

AIDS and Behavior · 2024-06 · 28 (6) · 2148-2155

DOI: 10.1007/s10461-024-04312-3 ↗

Kurz gefasst

Fachartikel in der Zeitschrift AIDS and Behavior, online erschienen am 13.04.2024. Verfasst von Lucky Makonokaya und 18 weiteren Autor:innen. Beteiligte Einrichtung: Elizabeth Glaser Pediatric AIDS Foundation, Lilongwe, Malawi. makonokayal@gmail.com. Hauptthemen laut MEDLINE: HIV Infections, Pyridones, Heterocyclic Compounds, 3-Ring, Oxazines. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: U.S. President's Emergency Plan for AIDS Relief, U.S. President’s Emergency Plan for AIDS Relief.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Viral suppression (VS) in children has remained suboptimal compared to that in adults. We evaluated the impact of transitioning children weighing < 20 kg to a pediatric formulation of dolutegravir (pDTG) on VS in Malawi. We analyzed routine retrospective program data from electronic medical record systems pooled across 169 healthcare facilities in Malawi supported by the Elizabeth Glaser Pediatric AIDS Foundation (EGPAF). We included children who weighed < 20 kg and received antiretroviral therapy (ART) between July 2021–June 2022. Using descriptive statistics, we summarized demographic and clinical characteristics, ART regimens, ART adherence, and VS. We used logistic regression to identify factors associated with post-transition VS. A total of 2468 Children Living with HIV (CLHIV) were included, 55.3% of whom were < 60 months old. Most (83.8%) had initiated on non-DTG-based ART; 71.0% of these had a viral load (VL) test result before transitioning to pDTG, and 62.5% had VS. Nearly all (99.9%) CLHIV transitioned to pDTG-based regimens. Six months after the transition, 52.7% had good ART adherence, and 38.6% had routine VL testing results; 81.7% achieved VS. Post-transition VS was associated with good adherence and pre-transition VS: adjusted odds ratios of 2.79 (95% CI 1.65–4.71), p < 0.001 and 5.32 (95% CI 3.23–9.48), p < 0.001, respectively. After transitioning to pDTG, VS was achieved in most children tested within the first 6 months. However, adherence remained suboptimal post-transition and VL testing at 6 months was limited. Interventions to improve VL testing and enhance ART adherence are still needed in CLHIV on pDTG-based regimens.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV InfectionsPyridonesHeterocyclic Compounds, 3-RingOxazinesViral LoadPiperazinesDrug MonitoringHumansMalawiMaleFemaleRetrospective StudiesChild, PreschoolInfantHIV Integrase InhibitorsAnti-HIV AgentsChildAdolescentDolutegravir

Stichwörter der Autor:innen

AdherenceAntiretroviral therapyChildren living with HIVMalawiPediatric dolutegravirViral suppression

Substanzen

PyridonesHeterocyclic Compounds, 3-RingOxazinesPiperazinesHIV Integrase InhibitorsAnti-HIV AgentsDolutegravir

Autor:innen und Institutionen

  • Elizabeth Glaser Pediatric AIDS Foundation, Lilongwe, Malawi. makonokayal@gmail.com.
  • U. S. Centers for Disease Control and Prevention, Division of Global HIV and TB, Lilongwe, Malawi.
  • Elizabeth Glaser Pediatric AIDS Foundation, Lilongwe, Malawi.
  • U. S. Centers for Disease Control and Prevention, Atlanta, USA.
  • Department of HIV and AIDS, Ministry of Health, Lilongwe, Malawi.
  • Elizabeth Glaser Pediatric AIDS Foundation, Washington, DC, USA.

Förderung

  • U.S. President's Emergency Plan for AIDS Relief
  • U.S. President’s Emergency Plan for AIDS Relief

Zitieren

APA

Makonokaya, L., Maida, A., Kalitera, L. U., Wang, A., Kapanda, L., Kayira, D., Bottoman, M., Nkhoma, H., Dunga, S., Joaki, Z., Chamanga, R., Nkanaunena, K., Hrapcak, S., Nyirenda, R., Chiwandira, B., Maulidi, M., Woelk, G., Machekano, R., & Maphosa, T. (2024). Early Effects of Scaling Up Dolutegravir-Based ARV Regimens Among Children Living with HIV in Malawi. AIDS and Behavior, 28(6), 2148-2155. https://doi.org/10.1007/s10461-024-04312-3

Vancouver

Makonokaya L, Maida A, Kalitera LU, Wang A, Kapanda L, Kayira D, et al. Early Effects of Scaling Up Dolutegravir-Based ARV Regimens Among Children Living with HIV in Malawi. AIDS and Behavior. 2024;28(6):2148-2155. doi:10.1007/s10461-024-04312-3

BibTeX
@article{Makonokaya2024,
  author = {Makonokaya, Lucky and Maida, Alice and Kalitera, Louiser Upile and Wang, Alice and Kapanda, Lester and Kayira, Dumbani and Bottoman, Madalitso and Nkhoma, Harrid and Dunga, Shalom and Joaki, Zuze and Chamanga, Rachel and Nkanaunena, Kondwani and Hrapcak, Susan and Nyirenda, Rose and Chiwandira, Brown and Maulidi, Martin and Woelk, Godfrey and Machekano, Rhoderick and Maphosa, Thulani},
  title = {Early Effects of Scaling Up Dolutegravir-Based ARV Regimens Among Children Living with HIV in Malawi},
  journal = {AIDS and Behavior},
  year = {2024},
  volume = {28},
  number = {6},
  pages = {2148--2155},
  doi = {10.1007/s10461-024-04312-3}
}
Kostenlos starten →